Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - See all

See all

A. Bengoetxea - P. D'Ans - J. Foucart - M. Schetgen - A. Spinewinne - L. Di Biagi - F. Defraine - M. Karam - J. Mellier - Q. Vanderhofstadt

ULB, UCLouvain, Université de Montréal
" OBJ: 1) Observe interprofessional and interorganisational collaboration "in the making" in crisis situation: how professional groups organize and collaborate (within and between professional groups) in different organizational contexts (liberal practice, primary care delivery services, hospitals, nursing homes, etc.) especially for vulnerable groups. 2) Analyse the role of regulatory bodies governmental agencies, professional associations) in managing healthcare professions and interprofessional collaboration in crisis situations 3)Improving future care and the resilience of health systems METH: Collection and analysis of documents (instructions, tools, etc.), qualitative interviews, in situ observations. Developing Grounded theory "
Funding: Research team is part of BeHive - Interdisciplinary primary care Chair, funded by the King Baudouin Foundation (Fund Dr. Daniel De Coninck)
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

A. Marchant - S. Goriely - N. Dauby - S. De Wit - O. Vandenbergh - C. Montesino - V. Mascart - V. Del Marmol - A. Le Moine - F. Andris - C. Gueydan - A. Botteaux - A. Matagne

ULB, CHU Saint-Pierre, Hôpital Erasme, ULiège - FNRS

" The project investigates the immune responses to SARS-CoV-2 infection in humans. Cohorts of patients and contacts are recruited and followed-up during several months following infection. Using systems serology and systems biology approaches, the quality and dynamics of antibody and cellular responses are analysed to identify correlates of protection against severe disease and to determine the duration of natural immunity to the virus. The project should provide insight in the host response to SARS-CoV-2 and should help define deconfinement strategies and develop prophylactic and therapeutic interventions against COVID-19. "
Funding: COVID 19 - ULB
Contact: Arnaud Marchant: This email address is being protected from spambots. You need JavaScript enabled to view it. Stanislas Goriely: This email address is being protected from spambots. You need JavaScript enabled to view it.

Adélaïde de Heering, Post-doctoral Fellow


Sphère publique, sphère privée : Impact du port du masque sur la reconnaissance des personnes et de l'expression émotionnelle de leur visage. " Le déconfinement approche. Bientôt la population belge sillonnera à nouveau les rues, les transports et l'ensemble de l'espace public mais munie de masques. Quels retentissements sur la capacité des personnes à en reconnaître d'autres sur base de leur visage et à en extraire l'expression émotionnelle ? Sera-t-on toujours capable de juger, de manière efficace, de l'intention d'autrui à notre égard même si cette dernière porte un masque ? A tous les âges ? Ou, au contraire, a-t-on raison d'avoir la suspicion que le port du masque pourrait nous empêcher de reconnaître quelqu'un sur base de son visage et d'en lire les émotions de manière efficace ? "
Publication References: de Heering, A., & Rossion, B. (2008). Prolonged Visual Experience in Adulthood Modulates Holistic Face Perception. PlosOne, 3(5): e2317. de Heering, A., &amp...

Alain Bosseloir, COO

" Development of specific IVD products to detect the patient serology due to the infection with SARS-COV2 Developement based on ISO13485, Directives 98/79/EC standards. Different technologies approched : ELISA, RT-PCR, lateral flow "
Contact: Alain Bosseloir COO ZenTech sa Liege Science Park Avenue du Pré Aily 10 4031 Angleur

Alexandre Di Paolo, Business Development Manager

Xpress Biologics
" Xpress Biologics, a Belgian based CDMO, has several strategies to tackle the COVID-19 pandemic which includes: - The development of a serology assay to detect Covid-19 seroconversion in humans based on the manufacturing of 3 specific COVID-19 antigens ( full-length Spike protein, S1 subunit, RBD domain) using Pichia pastoris as expression system - Plasmid DNA manufacturing expertise for the development of anti-COVID DNA vaccines - Recombinant protein or antibody fragments manufacturing expertise for diagnostic and treatment of COVID-19 Xpress Biologics has adapted technological platforms that are available to meet the COVID-19 pandemic challenge. In particular our Molecular Biology solution can rapidly help us develop microbial strains for robust and efficient expression of several type of biologics such as viral antigens, neutralizing antibody fragments and DNA vaccines while through our Upstream Process platform we can rapidly engineer industrial processes for...

Alexandre Le Vert, Executive Chairman and Cofounder

" OSIVAX is using its proven vaccination approach in Influenza (OVX836 currently in phase 2a clinical trial) to develop a broadly protective coronavirus vaccine triggering CD8 T-cell responses against the Nucleocapsid. This approach is based on evidence that CD8 T-cell responses against Nucleocapsid are protective in animals and humans. OSIVAX is currently down-selecting Nucleocapsid sequences with the aim to produce first lab-scale batches in the coming weeks. "
Funding: OSIVAX is currently seeking funding from European institutions supporting the development of vaccines against COVID-19.
Contact: Alexandre Le VERT This email address is being protected from spambots. You need JavaScript enabled to view it.

Alfred Attipoe, CEO

Comunicare Solutions
" Comunicare Solutions is a health technology startup, specializing in patient empowerment, self-management and digital therapy. In the context of Covid-19 sanitary crisis, we proposed our solution for the remote support to chronic patients, especially the most at risk patients who suffered from chronic systemic diseases of respiratory origin, such as chronic obstructive pulmonary disease (COPD) and heart disease like heart failure or complex hypertension. The application enables caregivers to inform those patients about additional precautions, to screen patients reported outcomes but also to keep in touch with them via video consultation"
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

André Matagne, Alain Brans, Marylène Vandevenne, Maximiliano Figueroa, Moreno Galleni, Romain Malempré

ULiège - Royal Academy of Sciences, Letters and Fine Arts of Belgium
"The Centre for Protein Engineering (CIP, ULiège), through its two technological platforms, has been involved in the production of reagents (i.e. proteins) for diagnostic and analyses of SARSCoV-2 infection. In particular, Protein Factory has produced a pure and highly active enzyme (CAS12) for a CRISPR/CAS assay, which, in combination with classical PCR technology allows rapid detection of the virus. Automated screening is currently performed at Robotein for optimal formulation of CAS12. The production of complementary protein reagents for such tests is underway. Furthermore, in a collaborative effort with Dr Arnaud Marchant at Institut d'Immunologie Médicale (ULB), the CIP is involved in the design and production of recombinant SARS-COV-2 antigens towards the development of a platform for high dimensional systems serology analysis of SARS-CoV-2 antibodies."
Contact: André Matagne This email address is being protected from spambots. You need JavaScript enabled to view it. 

Anne Van den Broeke, Doctor

Institut Jules Bordet
" Contribution to the application and implementation of a novel Covid-19 diagnostic testing method developed at the GIGA/FARAH academic research institutes. Starting with a handful academic scientists from different disciplines, we established a Covid diagnostic lab with the goal of increasing the testing capacity in Belgium during the heaviest period of the crisis. The lab was entirely and exclusively build by training academic volunteers dedicating their time and energy to a joint effort to "beat the virus". Today the lab has a testing capacity of > 3000 samples/day, 7days/7. The diagnostic lab contributed - and still contributes - to the federal Testing Task Force as one of the five partners involved in screening nursing homes and more recently "centres de triage". We believe extensive testing may be critical to assist and better understand the nascent "deconfinement". Making available our expertise in virus-associated diseases accumulated over years of...

Annick Sartenaer, Full Professor - Alexandre Mauroy, Professor - Nicolas Franco, Ph. D. - Sébastien Clesse, Ph. D.- Morgane Dumont, Ph.D. Student

UNamur - FNRS
" Professors and researches from the Department of Mathematics and the naXys research institute of complex systems at UNamur gathered their skills and expertise in mathematical modeling, dynamic systems, statistics, control theory and numerical optimization to develop prediction and unlockdown monitoring models of the Covid-19 epidemic. They set up a consortium in mathematical modeling of the Covid-19 epidemic bringing together all the universities of the Wallonia Brussels Federation, in synergy with its equivalent in Flanders. "
Contact: Annick Sartenaer (This email address is being protected from spambots. You need JavaScript enabled to view it.) Alexandre Mauroy (This email address is being protected from spambots. You need JavaScript enabled to view it.) Nicolas Franco (This email address is being protected from spambots. You need JavaScript enabled to view it.) Sébastien Clesse (This email address is being protected from spambots. You need JavaScript enabled to view it.) Morgane Dumont (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Benoît Muylkens, Professor - Nicolas Gillet, Professor

UNamur - Royal Academy of Medicine of Belgium - Royal Academy of Sciences, Letters and Fine Arts of Belgium
" UNamur researchers have developed a procedure for the detection of SARS-CoV-2. The protocol has been approved by the Federal Agency for Medicines and Health Products (FAMHP). As successfully realized within UNamur, the method can be implemented in a molecular biology research lab to be used for diagnostic purposes on clinical samples. It requires little technological development and allows to overcome reagents shortage or availability of automated systems. To support the implementation of the diagnostic procedure, the required equipment and logistical means have been described in a "starting pack" document accompanying the protocol. "
Publication References: The protocol and starting pack can be downloaded here: https://www.narilis.be/news/sana-sars-cov-2-namur
Contact: Virginie Bourguignon This email address is being protected from spambots. You need JavaScript enabled to view it.

Caroline Daelemans, Professor

"Our objectives are: • To study maternal and neonate COVID-19 information in the Belgian-Obstetric Surveillance System database: clinical presentation and natural history of disease, pregnancy-related basic information, pregnancy outcomes, birth characteristics, infant morbidity and mortality. • To study the core socio-demographic information to potentially identify groups at higher risk of complications • Build a more informative dataset thanks to data mining of public databases This study will enable us to understand the impact of COVID-19 on pregnant women and their offspring in Belgium, and in the world via the contribution to the INOSS multicenter study. It might allow us to define an at-risk population among pregnant women and their offspring, and tailor epidemiologic and clinical interventions for these more vulnerable individuals."
Funding: Pending (FNRS)
Publication References: "1. The International Network of Obstetric Survey Systems study of uterine rupture: a...

Caroline Daelemans, Professor

" COVerT Our aim is to delineate more accurately the prevalence of the infection in the pregnant population and study vertical transmission in the cord blood of babies born to mothers with confirmed SARS-CoV-2 infection. Determination of prevalence of SARS-CoV-2 infection in mothers by combined universal screening: presence of antibodies (IgG and IgM or IgA) in their blood and/or a positive RT-PCR in the nasopharyngeal swab. We intend to detect evidence of vertical transmission by the identification of SARS-CoV-2 specific IgM or IgA in cord blood samples. If there is evidence of vertical transmission, the analysis of the consequences depending on infection timing during pregnancy will enable us to guide management more precisely. "
Funding: pending FNRS
Publication References: "1. Delforge ML, Costa E, Brancart F, Goldman D, Montesinos I, Zaytouni S, Marchant A, Donner C Presence of cytomegalovirus in urine and blood of pregnant women with primary infection might be associated...

Cedric Szpirer, Executive & Scientific Director

Delphi Genetics SA
" The aim of the project is to develop an antiviral gene therapy specifically targeting Covid-19. The benefits should be (i) targeting precisely the virus directly in lung cells allowing limitation of virus development from the starting point, (ii) restoring essential functions of the patient's cells and (iii) antibodies production by the patient due to reduction of viral load but not immediate clearance. In addition, the therapy could also be used preventively for people who come into regular contact with affected patients. The therapy is a gene therapy using AAV for patient administration. Delphi Genetics is developing and producing the plasmids required for targeting the virus and production of AAV. "
Contact: Cedric Szpirer Delphi Genetics SA 071 25 10 00

Charles Pilette, Professor

UCLouvain, St-Luc
" We aim to characterize the reprogramming of structural cells of the lungs that are direct targets of the SARS-CoV-2, namely type 2 alveolar epithelial cells and endothelial cells, as well as their potential role in the induction of the (hyper)inflammatory phase of the disease leading to acute lung injury. The skills of our laboratory in lung and mucosal immunology research that are relevant to this field are (1) access to precious human lung tissue (e.g. from SARS-CoV-2 patients), (2) multiplex immunofluorescence staining and isolation of structural cells (e.g. alveolar epithelial cells, endothelial cells) from the human lung, as well as (3) their characterization using cell culture-based readouts and (in collab. with the UCL-CTMA) genetic sequencing. "
Funding: FNRS CUR, application submitted on 01-05-20.
Publication References: 1. Gohy ST, Hupin C, Fregimilicka C, Detry BR, Bouzin C, Gaide Chevronay H, Lecocq M, Weynand B, Ladjemi MZ, Pierreux CE, Birembaut P...

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11


Brussels & Wallonia against COVID19